June 28, 2012
There will no doubt be disappointment on final guidance from NICE this week rejecting the use of GlaxoSmithKline's Tyverb and Roche's Herceptin for a subset of patients with breast cancer on the National Health Service.
February 17, 2012
GlaxoSmithKline has withdrawn one submission to expand the label on Tyverb in Europe, after the regulator expressed concerns about the data, but has filed fresh regulatory applications on both sides of the Atlantic for the breast cancer drug
February 14, 2012
Cost regulators for the National Health Service in England and Wales are sticking with their initial decision to reject the use of GlaskoSmithKline's Tyverb and Roche's Herceptin alongside hormone therapy in certain postmenopausal breast cancer patients.
October 14, 2010
GSK has lost its appeal to overturn NICE draft guidance on the use of Tyverb in National Health Service patients with breast cancer, but the Institute wants to consider the drug in a different appraisal alongside Roche's Herceptin instead.
PharmaTimes 2013 Copyright | RSS Feed Subscriptions Website by DCSL Software